This site is only for UK healthcare professionals and contains promotional information.

Prescribing Information can be found at the bottom of this page.

Marc

Has signs of metabolic syndrome

  • Marc

Marc, 63

Profile

  • Diabetes, high blood pressure and obesity suggest metabolic syndrome1
  • This is up to a third more prevalent in psoriasis patients than the general population1–3

Treatment goals

  • Any treatment must take his metabolic syndrome into account
  • Marc travels a lot for work and leisure, so wants a treatment he can take with him

“Psoriasis is a real drain on my energy.”

The benefits of ILUMETRI® for Marc:

RESPONSE RATES NOT AFFECTED BY METABOLIC SYNDROME
(post hoc analysis)2

CONVENIENT DOSING SCHEDULE
with up to 30 days’ refrigerator-free storage up to 25oC4

IMPROVED QUALITY OF LIFE5

THE ONLY IL-23p19 WITH FLEXIBLE DOSING
(100 or 200 mg)4

PASI 75, 90 and 100 responses are well-maintained for up to 5 years of treatment with ILUMETRI®6

Suffers with moderate itch
Has signs of metabolic syndrome

You might also be interested in

ILUMETRI® metabolic syndrome patient profile
Download additional information about the benefits of ILUMETRI® for patients with metabolic syndrome
Watch the video

Discover your reason to prescribe ILUMETRI®

German case report

An ILUMETRI® case report demonstrating results in the real world

References

  1. Singh S, et al. PLoS ONE 2017;12:e0181039.
  2. Lebwohl MG, et al. J Am Acad Dermatol 2021;84:398–407.
  3. Fernández-Armenteros JM, et al. J Eur Acad Dermatol Venereol 2019;33:128–135.
  4. ILUMETRI® Summary of Product Characteristics. Almirall.
  5. Reich K, et al. Lancet 2017;390:276–288.
  6. Thaçi D, et al. Br J Dermatol 2021. DOI: 10.1111/bjd.19866.

UK-ILU-2100104 November 2021

My Favorites